Patents
Literature
2 results about "Endorphins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Endorphins (contracted from "endogenous morphine") are endogenous opioid neuropeptides and peptide hormones in humans and other animals. They are produced by the central nervous system and the pituitary gland. The term "endorphins" implies a pharmacological activity (analogous to the activity of the corticosteroid category of biochemicals) as opposed to a specific chemical formulation. It consists of two parts: endo- and -orphin; these are short forms of the words endogenous and morphine, intended to mean "a morphine-like substance originating from within the body". The class of endorphins includes three compounds—α-endorphin (alpha endorphins), β-endorphin (beta endorphins), and γ-endorphin (gamma endorphins)—which preferentially bind to μ-opioid receptors. The principal function of endorphins is to inhibit the communication of pain signals; they may also produce a feeling of euphoria very similar to that produced by other opioids.
Esters of beta endorphin
PendingUS20250360221A1Peptide/protein ingredientsPharmaceutical non-active ingredientsEster prodrugMetabolite
Chronic intractable pain is a global health issue, highlighting the need for a potent μ-agonist analgesic with minimal major side effects. Intrathecal administration of β-endorphin in humans produces significant analgesia without respiratory depression or tolerance. Earlier animal studies concluding that chronic administration of β-endorphin results in tolerance and respiratory depression may not be applicable to humans due to differences between human and animal μ-receptors and β-endorphins. It is anticipated that β-endorphin functions as a GPCR biased ligand, similar to ligand binding in endocrinopathies that do not usually produce tolerance. Ester prodrugs of β-endorphin are predicted to cross the human blood-brain barrier (BBB), undergo hydrolysis to β-endorphin and a non-toxic metabolite, and provide substantial analgesia with low toxicity and without major side effects. The synthesis of lead prodrugs is described. Compared to current pharmaceutical development expenditures, the risks associated with this research are considered low.
Owner:GOLDBERG JOEL STEVEN
Essential oil composition with repairing and anti-aging effects and application thereof
This invention belongs to the field of cosmetic composition technology, specifically relating to an essential oil composition with repairing and anti-aging effects and its application. The essential oil composition consists of carrot seed oil, white chamomile flower oil, and unsaponifiables from shea butter. This composition effectively promotes the release of endorphins from skin cells, helping to relieve skin stress; simultaneously, it significantly inhibits excessive cortisol secretion under stress, alleviating skin stress responses at their source. This composition exhibits excellent barrier repair capabilities, promoting keratinocyte migration and scratch healing, upregulating the expression of barrier-related genes, and effectively scavenging UV-induced reactive oxygen species, reducing oxidative damage. Furthermore, this composition significantly promotes the expression of type I and type III collagen, exerting repairing and anti-aging effects from multiple perspectives.
Owner:Hangzhou Yumei Biotechnology Co., Ltd.